CAESAREA, Israel, March 30, 2017 /PRNewswire/ --
DARIOHEALTH CORP. ("DARIO") (NASDAQ: DRIO), a leading global digital health company with mobile health and big
data solutions, announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The
company intends to use the net proceeds from this offering for commercialization efforts of its products, including
increased marketing and production expenses, and for general working capital purposes. The offering is subject to market
conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms
of the offering.
(Logo: http://photos.prnewswire.com/prnh/20160802/395077LOGO )
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
The shares described above are being offered by Dario pursuant to a shelf registration statement (File No. 333-212644) that
was previously filed with, and declared effective by, the Securities and Exchange Commission ("SEC"). A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's
website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus
relating to this offering may be obtained, when available, from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a
unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have
direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood
Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for
self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional
office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Forward Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the
generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For
example, statements regarding the proposed public offering are forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could cause such results to differ materially from any
forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are
not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to,
those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for
Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as
required by applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-800-896-9062
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331
SOURCE DarioHealth Corp.